Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.


Arrhythmogenic Inflammatory Cardiomyopathy: A Review


Arrhythmia & Electrophysiology Review 2018;7(3):181–6.

AF Ablation in Patients with Heart Failure


Arrhythmia & Electrophysiology Review 2018;7(2):84–90.

Treatment of Atrial Fibrillation in Patients with Coexisting Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?


Arrhythmia & Electrophysiology Review 2018;7(2):91–4.

Premature Ventricular Contraction-induced Cardiomyopathy


Arrhythmia & Electrophysiology Review 2017;6(4):153–5.